A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma
Y Song, J Wu, X Chen, T Lin, J Cao, Y Liu, Y Zhao… - Clinical Cancer …, 2019 - AACR
Y Song, J Wu, X Chen, T Lin, J Cao, Y Liu, Y Zhao, J Jin, H Huang, J Hu, J Luo, L Zhang…
Clinical Cancer Research, 2019•AACRAbstract Purpose: For classical Hodgkin lymphoma (cHL), programmed death-l (PD-1) is a
well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the
efficacy and safety of camrelizumab, a humanized high-affinity IgG4 mAb against PD-1, in
Chinese patients with relapsed or refractory cHL. Patients and Methods: Patients who had
failed to achieve a remission or experienced progression after autologous stem cell
transplantation or had received at least two lines of systemic chemotherapies were given …
well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the
efficacy and safety of camrelizumab, a humanized high-affinity IgG4 mAb against PD-1, in
Chinese patients with relapsed or refractory cHL. Patients and Methods: Patients who had
failed to achieve a remission or experienced progression after autologous stem cell
transplantation or had received at least two lines of systemic chemotherapies were given …
Purpose
For classical Hodgkin lymphoma (cHL), programmed death-l (PD-1) is a well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the efficacy and safety of camrelizumab, a humanized high-affinity IgG4 mAb against PD-1, in Chinese patients with relapsed or refractory cHL.
Patients and Methods
Patients who had failed to achieve a remission or experienced progression after autologous stem cell transplantation or had received at least two lines of systemic chemotherapies were given camrelizumab 200 mg every 2 weeks. The primary endpoint was objective response rate per independent review committee (IRC) assessment. This study is registered with ClinicalTrials.gov (NCT03155425).
Results
Between June 9, 2017 and September 18, 2017, 75 patients were enrolled and treated. At a median follow-up of 12.9 months, 57 of 75 (76.0%; 95% CI, 64.7–85.1) patients achieved an IRC-assessed objective response, including 21 (28.0%) and 36 (48.0%) patients who had complete and partial remission, respectively. Median duration of response was not reached (range, 0.0+–12.8+ months). Treatment-related adverse events (AE) occurred in all patients. The most common ones included cutaneous reactive capillary endothelial proliferation (97.3%, 73/75) and pyrexia (42.7%, 32/75). Grade 3 or 4 treatment-related AEs occurred in 20 patients (26.7%); the most common AE was decreased white blood cell count (4.0%, 3/75). There were no grade 5 treatment-related AEs.
Conclusions
Camrelizumab demonstrated a high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.
AACR
